15 Global Dividend Stocks to Diversify Your Portfolio

2. GSK plc (NYSE:GSK)

Number of Hedge Fund Holders: 41

Dividend Yield as of December 27: 3.54%

GSK plc (NYSE:GSK) is one of the best dividend stocks to invest in.

On December 10, HSBC analyst Rajesh Kumar raised the firm’s price target on GSK plc (NYSE:GSK) to 1,500 GBp from 1,200 GBp and kept a Reduce rating on the shares. The move came as part of HSBC’s 2026 outlook for the pharmaceutical sector. The firm said the group is positioned to outperform next year, “even more so if AI panic kicks in.”

HSBC added that its preferred names sit in the “growth bucket ideas,” though it noted that “fallen angels and value could work as well.”

A few days later, on December 16, GSK plc (NYSE:GSK) shared an update on the regulatory front. The US Food and Drug Administration approved the company’s add-on treatment for severe asthma, giving patients access to a therapy that requires less frequent dosing. At the same time, the agency declined to approve the drug for another condition.

The decision comes as GSK prepares for a leadership transition. Commercial chief Luke Miels is set to step into the CEO role early next year, at a time when the company is dealing with US tariffs and looking to replenish its pipeline as key patents approach expiry.

The FDA cleared Exdensur as an add-on maintenance treatment for patients aged 12 and older with severe eosinophilic asthma. The approval makes it the first biologic available with a twice-yearly dosing schedule. GSK said the agency did not approve the drug for the treatment of chronic rhinosinusitis with nasal polyps, a long-term inflammatory sinus condition.

In the UK, regulators had already approved the drug, branded as Exdensur, for use as an add-on asthma treatment in patients aged 12 and older. UK authorities also cleared it for chronic rhinosinusitis with nasal polyps in adults, a broader label than what the FDA granted.

GSK plc (NYSE:GSK) operates as a global biopharmaceutical company focused on developing medicines and vaccines, with core strengths in respiratory disease, immunology, and infectious diseases.